. Author manuscript; available in PMC: 2015 Dec 1.

Published in final edited form as: Cancer Immunol Immunother. 2015 Sep 21;64(12):1531–1539. doi: 10.1007/s00262-015-1758-5

TABLE 1.

Class I MHC-restricted vaccine (12MP) trial protocols for patients with high-risk melanoma

Trial	Peptide	Adjuvant	N	Gender, M	Age, <64y	IR+ (%)
Mel43^a	12MP;tetanus	IFA + GM-CSF	58	37	47	20 (34%)
		IFA	60	45	46	44 (73%)
Mel44^a	12MP;tetanus	IFA+/− cyclophos	82	53	57	58 (71%)
	12MP:6MHP	IFA+/− cyclophos	85	59	64	18 (21%)
Mel48^a,b	12MP;tetanus	IFA	42	30	35	20 (48%)
Total			327^c	M 224	<64y 249	+ (49%)
				F 103	≥64y 78	− (51%)

MHC major histocompatibility complex, 12MP 12 class I MHC-restricted melanoma peptides, IFA incomplete Freund's adjuvant, GM-CSF granulocyte-macrophage colony-stimulating factor, 6MHP 6 class II MHC-restricted melanoma helper peptides, IR Immune response

Ten vaccinations were administered for Mel43 and Mel44 and 6 for Mel48

Patients with nonmeasurable disease or equivocal findings may be enrolled in Mel48

One participant belonged to both trials 43 and 48